Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the Malignant Germ Cell International Consortium perspective.
Document Type
Article
Publication Date
3-1-2024
Original Citation
Pashankar F,
Murray M,
Gell J,
MacDonald N,
Shamash J,
Billmire D,
Klosterkemper L,
Olson T,
Hirsch M,
Lockley M,
Stoneham S,
Frazier A.
Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the Malignant Germ Cell International Consortium perspective. EClinicalMedicine. 2024;69:102453
Keywords
JGM
JAX Source
EClinicalMedicine. 2024;69:102453
ISSN
2589-5370
PMID
38544795
DOI
https://doi.org/10.1016/j.eclinm.2024.102453
Abstract
Ovarian immature teratoma (IT) is a rare neoplasm comprising ∼3% of ovarian cancers, occurring primarily in young females. Management presents several challenges, including those with elevated serum alpha-fetoprotein, potential confusion regarding pathology interpretation, and paucity of data to support decision-making. MaGIC (https://magicconsortium.com/) is an interdisciplinary international consortium of GCT experts from multiple subspecialties, with members receiving frequent queries regarding IT patient management. With evidence from published literature where available, we summarise consensus management of such patients. Given lack of published data, controversy in certain areas remains. The most obvious variance in practice is between paediatric and adult teams, despite very similar outcomes. Paediatric teams typically employ a surgery-only approach, whereas in adult practice, all patients, except those with stage IA, grade 1 (low-grade) tumours, still generally receive adjuvant chemotherapy. Given the rarity of ovarian IT and lack of published data, discussion with GCT experts and/or national advisory panels is recommended.